BioMarin Pharmaceutical, NASDAQ and BMRN
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...
Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...
Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 ...
Full Year 2024 Results Key Financial Results Revenue: US$2.85b (up 18% from ...
Shares of BioMarin Pharmaceutical climbed after better fourth-quarter earnings and revenue topped analyst views and the company provided upbeat revenue guidance. The stock was up 5% at $68.87 in ...
UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback